Using two-colour flow cytometry>200 antibodies submitted to the 8^(th) International Workshop of Human Leukocyte Differentiation Antigens(HLDA8)have been analyzed for their reactivity with resting and activated CD2...Using two-colour flow cytometry>200 antibodies submitted to the 8^(th) International Workshop of Human Leukocyte Differentiation Antigens(HLDA8)have been analyzed for their reactivity with resting and activated CD203c^(+)basophils.Four antibodies either non-reactive or weakly reactive with resting basophils exhibited an increased reactivity with basophils activated by anti-IgE-mediated cross-linking of the high affinity IgE receptor(FcεRI).These include antibod-ies against CD164(WS-80160,clone N6B6 and WS-80162,clone 67D2),as well as two reagents with previously unknown specificities that were identified as CD13(WS-80274,clone A8)and CD107a(WS-80280,clone E63-880).The activation patterns followed either the“CD203c-like”or“CD63-like”activation profile.The CD203c profile is characterized by a rapid and significant upregulation(of CD13,CD164,and CD203c),reaching maximum levels after 5-15 min of stimulation.The phosphoinositide-3-kinase(PI3K)-specific inhibitor wortmannin inhibited the upregulation of these markers whereas 12-O-tetradecanoyl-phorbol-13-acetate(TPA)induced a rapid and FcεRI-independent upregulation within 1-2 min.In the CD63 profile,maximum upregulation(of CD63 and CD107a)was detected only after 20-40 min,and upregulation by TPA reached maximum levels after 60 min.In summary,our data identify CD13,CD107a,and CD164 as novel basophil-activation antigens.Based on time kinetics of upregulation,we hypothesize that molecules of the“CD203c group”and the“CD63 group”are linked to two different mechanisms of basophil activation.展开更多
In 2002, the Vienna Cancer Stem Cell Club （VCSCC） was inaugurated by a group of scientists at the Medical University of Vienna, with the primary goal to initiate and promote cancer stem cell （CSC） research in Aust...In 2002, the Vienna Cancer Stem Cell Club （VCSCC） was inaugurated by a group of scientists at the Medical University of Vienna, with the primary goal to initiate and promote cancer stem cell （CSC） research in Austria and to exploit knowledge from this new discipline in translational approaches, During the first years following inauguration, the VCSCC-community was small and left without major funding. However, over time the consortium was able to launch several major project-lines, supported in part by the National Science Funds, a Genome Program, and the Ludwig-Boltzmann Society. Today, the VCSCC provides a robust intellectual platform for ongoing research in the field of translational oncology and CSC-research in Austria. In addition, the VCSCC is connected to several major CSC-networks and centers in Europe and in North America, and is a well-recognized group in the field. The VCSCC also organized a series of CSC Meetings and Conferences, and contributed essentially to a recently published classification of CSC. There is also hope that the VCSCC-consortium will further advance the field of CSC research in the future, and will create novel concepts, with the ultimate aim to improve anti-cancer therapy through elimination, suppression, or long-term control of cancer-initiating cells.展开更多
基金This work was supported by a grant from the Deutsche Forschungsgemeinschaft,SFB 510-A1(F.H.and H.-J.B.),by the fortueneproject F1282700 of the univer-sity of Tuebingen(H.-J.B)by the Fonds zur Forderung der wissnschaflichen Forschung in Osterreich,SFB grant-project 018/09(P.V.).
文摘Using two-colour flow cytometry>200 antibodies submitted to the 8^(th) International Workshop of Human Leukocyte Differentiation Antigens(HLDA8)have been analyzed for their reactivity with resting and activated CD203c^(+)basophils.Four antibodies either non-reactive or weakly reactive with resting basophils exhibited an increased reactivity with basophils activated by anti-IgE-mediated cross-linking of the high affinity IgE receptor(FcεRI).These include antibod-ies against CD164(WS-80160,clone N6B6 and WS-80162,clone 67D2),as well as two reagents with previously unknown specificities that were identified as CD13(WS-80274,clone A8)and CD107a(WS-80280,clone E63-880).The activation patterns followed either the“CD203c-like”or“CD63-like”activation profile.The CD203c profile is characterized by a rapid and significant upregulation(of CD13,CD164,and CD203c),reaching maximum levels after 5-15 min of stimulation.The phosphoinositide-3-kinase(PI3K)-specific inhibitor wortmannin inhibited the upregulation of these markers whereas 12-O-tetradecanoyl-phorbol-13-acetate(TPA)induced a rapid and FcεRI-independent upregulation within 1-2 min.In the CD63 profile,maximum upregulation(of CD63 and CD107a)was detected only after 20-40 min,and upregulation by TPA reached maximum levels after 60 min.In summary,our data identify CD13,CD107a,and CD164 as novel basophil-activation antigens.Based on time kinetics of upregulation,we hypothesize that molecules of the“CD203c group”and the“CD63 group”are linked to two different mechanisms of basophil activation.
文摘In 2002, the Vienna Cancer Stem Cell Club （VCSCC） was inaugurated by a group of scientists at the Medical University of Vienna, with the primary goal to initiate and promote cancer stem cell （CSC） research in Austria and to exploit knowledge from this new discipline in translational approaches, During the first years following inauguration, the VCSCC-community was small and left without major funding. However, over time the consortium was able to launch several major project-lines, supported in part by the National Science Funds, a Genome Program, and the Ludwig-Boltzmann Society. Today, the VCSCC provides a robust intellectual platform for ongoing research in the field of translational oncology and CSC-research in Austria. In addition, the VCSCC is connected to several major CSC-networks and centers in Europe and in North America, and is a well-recognized group in the field. The VCSCC also organized a series of CSC Meetings and Conferences, and contributed essentially to a recently published classification of CSC. There is also hope that the VCSCC-consortium will further advance the field of CSC research in the future, and will create novel concepts, with the ultimate aim to improve anti-cancer therapy through elimination, suppression, or long-term control of cancer-initiating cells.
